Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PG4 Multivalent Vaccine

Vaccine · Immune activation · developed by Pfizer

Phase 3 Most advanced trial
PFE Developer
1 Registered trials

What is PG4 Multivalent Vaccine?

PG4 Multivalent Vaccine is a multivalent pneumococcal vaccine intended to induce immunity against Streptococcus pneumoniae infection. It is being studied in pneumococcal disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PG4 Lot 3
Drug type
Vaccine
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
Pfizer (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07794748 Phase 3 Pneumococcal Disease Active not recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pneumococcal Disease

More from Pfizer

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind PG4 Multivalent Vaccine

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.